SEQUESSOME TECHNOLOGY
DEAD

Serial Number

79115050

Owner

Pro Bono Bio Entrepreneur Limited

Attorney

Roberta S. Bren

Filing Date

Dec 20, 2011

Add to watchlist:

No watchlists yet
View on USPTO

SEQUESSOME TECHNOLOGY Trademark

Serial Number: 79115050 • Registration: 4427020

SEQUESSOME TECHNOLOGY is a trademark filed by Pro Bono Bio Entrepreneur Limited on December 20, 2011. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

Pro Bono Bio Entrepreneur Limited (10 trademarks)

4th floor,

Entity Type: 99

Trademark Details

Filing Date

December 20, 2011

Registration Date

November 5, 2013

Published for Opposition

August 20, 2013

Cancellation Date

May 17, 2024

Goods & Services

Pharmaceutical preparations and substances for the treatment of pain and inflammation; [ veterinary and sanitary preparations and substances for the treatment of pain and inflammation; chemical preparations for pharmaceutical purposes, namely, for the treatment of pain and inflammation; pharmaceuticals for the treatment of osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; anti-inflammatory drugs; ] medicated creams, medicated dispersions, medicated lotions, medicated ointments, medicated gels [, medicated solutions, medicated sprays, medicated lacquers and pharmaceutical solutions which form a film on the skin for the treatment of pain or inflammation; chemical preparations for pharmaceutical or medical purposes, namely, the treatment of pain and inflammation; pharmaceuticals in the fields of osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal disease and central nervous system diseases, namely, vesicles which physically absorb and remove chemicals; pharmaceutical preparations, namely, topical and parenteral preparations in the form of vesicles; pharmaceutical preparations in the form of vesicles for medical and veterinary purposes; pharmaceutical preparations being chemical membranes and chemical aggregates for medical and veterinary purposes for the treatment of pain and inflammation; pharmaceutical preparations of arachidonic acids for the treatment of pain and inflammation; dispersions for pharmaceuticals for the treatment of pain and inflammation; medicated cosmetic and veterinary preparations, namely, dispersions and dry preparations of liposomal active substance carriers for the treatment of pain and inflammation; cosmeceutical preparations in the nature of medicated cosmetics; pharmaceutical preparations, namely, lipids for topical and parenteral use for the treatment of pain and inflammation; surfactants for medical use dispersed in the form of liquids, creams, gels, lotions, or liquid treatment sprays and lotions, being pharmaceutical preparations for the treatment of or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque-type psoriasis, seborrhoeic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea, hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, Alzheimer's disease, gout, macular degeneration, fungal disease and disorders related to fatty acid deficiencies ]

[ Medical devices in the nature of a carrier with nanostructures which cross through the skin allowing subcutaneous absorption for the treatment of pain; ] molecular filtering devices for medical use, namely, a liquid, gel or cream preparation as a drug delivery device which filters through or migrates into the skin and has a physical therapeutic effect; medical [ and veterinary ] devices, namely, a medical device in which vesicles act as a drug delivery device in the nature of non-pharmaceutical nanostructures that migrate through the skin and which contribute to the lubricating properties of synovial fluid [ ; medical instruments and devices for the administration of skin disease therapy and pain therapy and prophylaxis preparations and substances ]

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Apr 19, 2025 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Apr 1, 2025 INTS
INVALIDATION PROCESSED
Apr 1, 2025 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 18, 2025 INTR
CANCELLED SECTION 71
May 17, 2024 C71T
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Nov 5, 2022 REM4
INTERNATIONAL REGISTRATION RENEWED
Jan 7, 2022 RNWL
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Jan 7, 2020 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Jan 7, 2020 C75A
NEW REPRESENTATIVE AT IB RECEIVED
Jan 3, 2020 NREP
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 9, 2019 APRE
TEAS SECTION 71 & 15 RECEIVED
Nov 5, 2019 ES75
NEW REPRESENTATIVE AT IB RECEIVED
Aug 9, 2019 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 5, 2018 REM3
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 14, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 14, 2016 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 28, 2014 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 7, 2014 FICS
FINAL DISPOSITION PROCESSED
Feb 7, 2014 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 5, 2014 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 5, 2013 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 20, 2013 NPUB
PUBLISHED FOR OPPOSITION
Aug 20, 2013 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 31, 2013 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 17, 2013 PREV
ASSIGNED TO LIE
Jul 17, 2013 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 17, 2013 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 15, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 15, 2013 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 15, 2013 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 8, 2013 GNFN
FINAL REFUSAL E-MAILED
Mar 8, 2013 GNFR
FINAL REFUSAL WRITTEN
Mar 8, 2013 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 14, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2013 CRFA
ASSIGNED TO LIE
Feb 12, 2013 ALIE
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 11, 2013 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 11, 2013 REAP
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 11, 2013 TROA
REFUSAL PROCESSED BY IB
Sep 1, 2012 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 10, 2012 RFCS
REFUSAL PROCESSED BY MPU
Aug 10, 2012 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 10, 2012 RFCR
NON-FINAL ACTION WRITTEN
Aug 9, 2012 CNRT
APPLICATION FILING RECEIPT MAILED
Aug 7, 2012 MAFR
ASSIGNED TO EXAMINER
Aug 3, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 3, 2012 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 2, 2012 REPR